Simultaneous estimation of canagliflozin and metformin hydrochloride in tablet dosage form by UV spectrophotometry

Abstract

The combination of Canagliflozin and Metformin was available as fixed dose tablets for the treatment of type 2 diabetes. The present method aims to develop a simple, precise and accurate spectrophotometric method for simultaneous determination of Canagliflozin and Metformin in commercial formulation. The method utilizes Vierordt’s equation based on the measurement at two wavelengths 290nm (?max of Canagliflozin) and 236nm (?max of Metformin). The method exhibited linear range of 2.5 to 15µg/ml and 5 to 17.5µg/ml for Canagliflozin and Metformin, respectively, with a correlation coefficient of 0.999. The LOD and LOQ for Canagliflozin were found to be 0.43 and 1.31 respectively. For Metformin the LOD and LOQ were found to be 0.49 and 1.49 respectively. The recovery of Canagliflozin and Metformin were found to be 99.43 and 98.82 respectively. The results were validated statistically as per ICH guidelines and were found to be satisfactory. To conclude, the developed UV spectrophotometric method is more economical for analysis of Canagliflozin and Metformin in both bulk and pharmaceutical dosage form for routine analysis. Keywords: Canagliflozin, Metformin, Vierordt’s equation, UV-Spectrophotometry, ICH guidelines